Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Importance Effective treatments for patients with severe COVID-19 are needed. Objective To
evaluate the efficacy of canakinumab, an anti–interleukin-1β antibody, in patients …

Objectives To evaluate the effect of subcutaneous (sc) secukinumab, an interleukin-17A
inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic …

Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (…

Background Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the
signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and …

Emphysematous pyelonephritis most often presents as an acute medical emergency, typically
in a septic diabetic patient with acute renal failure. The management of this condition has …

Background Idiopathic inflammatory myopathy (IIM) is a multi-system autoimmune condition
characterised by muscle inflammation (myositis), interstitial lung disease (ILD), and skin …

Internet of Things (IoT) devices are well-connected; they generate and consume data which
involves transmission of data back and forth among various devices. Ensuring security of the …

SARS-CoV-2 has resulted in a global pandemic and an unprecedented public health crisis.
Recent literature suggests the emergence of a novel syndrome known as ‘long COVID’, a …